GSK Asks Philippines High Court To Reconsider Imports Decision
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline Philippines asked the Philippines Supreme Court to reconsider a decision that had the effect of declaring there is no law safeguarding the country from imported drugs not registered with the government. GSK wants a new look at a recent Supreme Court ruling that the Universally Accessible Cheaper and Quality Medicines Act of 2008 allows anyone to import and use medicines without fear of being prosecuted under the Counterfeit Drugs Act, which it declared void. GSK Philippines said the court in effect nullified the Bureau of Food and Drugs as well as the counterfeit law, so it filed a motion for the court to reconsider the decision. GSK said it had a different reading of the Cheaper Medicines Act, one that says the safeguards are in place. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.